Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lacutamab - Innate Pharma/University of Genoa

Next Previous
Drug Profile

Lacutamab - Innate Pharma/University of Genoa

Alternative Names: Anti-KIR3DL2 antibody; Anti-KIR3DL2 cytotoxic mAb; IPH 41; IPH4102

Latest Information Update: 15 May 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Genoa
  • Developer Innate Pharma; Lymphoma Academic Research Organisation
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; KIR3DL2 receptor antagonists; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cutaneous T-cell lymphoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Cutaneous T-cell lymphoma; Mycosis fungoides; Peripheral T-cell lymphoma; Sezary syndrome

Most Recent Events

  • 08 Jan 2026 Innate Pharma completes a phase II trial for Cutaneous T-cell lymphoma, Sezary Syndrome and Mycosis fungoides (Second-line therapy or greater) in France, Austria, Belgium, Spain, Italy, Germany, Poland, USA (IV) (NCT03902184)
  • 10 Nov 2025 Innate Pharma expects Accelerated Approval from US FDA for lacutamab in Sezary syndrome
  • 10 Nov 2025 Innate Pharma receives clearance from the US FDA for phase III TELLOMAK 3 trial for lacutamab in Sezary syndrome and Mycosis fungoides

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top